πŸ‡ΊπŸ‡Έ FDA
Patent

US 12343381

Dosage regimen for pegylated interferon

granted A61KA61K38/21A61K38/212

Quick answer

US patent 12343381 (Dosage regimen for pegylated interferon) held by PHARMAESSENTIA CORPORATION expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PHARMAESSENTIA CORPORATION
Grant date
Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K38/21, A61K38/212, A61K47/60, A61P